Guardant Health (NASDAQ:GH) Insider Terilyn Monroe Sells 10,031 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 10,031 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total transaction of $1,124,274.48. Following the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $2,352,559.20. This represents a 32.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Guardant Health Stock Performance

Guardant Health stock opened at $110.17 on Friday. Guardant Health, Inc. has a 1 year low of $34.80 and a 1 year high of $113.91. The firm has a 50 day moving average price of $102.14 and a 200 day moving average price of $73.15. The company has a market cap of $13.89 billion, a price-to-earnings ratio of -34.32 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The business’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.88) earnings per share. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on GH. Barclays raised their price objective on Guardant Health from $85.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Mizuho set a $135.00 price target on shares of Guardant Health in a report on Friday. Morgan Stanley raised their price objective on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Stifel Nicolaus boosted their target price on shares of Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday. Finally, TD Cowen upped their price objective on shares of Guardant Health from $63.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Twenty-two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average price target of $102.81.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the 4th quarter worth $28,000. Signaturefd LLC raised its stake in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares in the last quarter. IFP Advisors Inc raised its stake in Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares in the last quarter. Allworth Financial LP lifted its holdings in Guardant Health by 358.4% during the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after buying an additional 552 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at approximately $38,000. 92.60% of the stock is currently owned by institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.